AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01664052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESS305 (Essure, BAY1454032)
Description: Unilateral hysteroscopic placement of the permanent birth control system, Model ESS505 insert inclusive of polyethylene terephthalate (PET) fibers (investigational device model ESS505) and contralateral placement of the current commercially approved Essure device, model ESS305 followed by tubal occlusion evaluation by hysterosalpingogram (HSG) approximately 60 minutes following insert placement. A subsequent HSG was performed prior to the subjects' scheduled hysterectomy procedures at 30 (group 3), 60 (group 2) or 90 days (group 1) post insert placement. At the conclusion of the hysterectomy, the uterine cornua and fallopian tubes were sent to a pathology lab for histological preparation, and subsequent evaluation.
Study NCT01664052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESS505-A (Essure, BAY1454033)
Description: Bilateral hysteroscopic placement of the permanent birth control system, Model ESS505 insert with minimal polyethylene terephthalate (PET) fibers (investigational device model ESS505-A) followed by tubal occlusion evaluation by hysterosalpingogram (HSG) approximately 60 minutes following insert placement. A subsequent HSG was performed prior to the subjects' scheduled hysterectomy procedures at 30 (group 3), 60 (group 2) or 90 days (group 1) post insert placement.
Study NCT05676606 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote 1-minute single-lead electrocardiogram (ECG) monitoring in cancer patients after the first polychemotherapy cycle.
Description: Recording of the ECG using smart-phone at rest, 15 minutes before registering ECG patient should not smoke,having tea, coffee, alcohol. During the ECG recording hands should be fixed to avoid poor quality. Patient sitting on a char with tow hands fixed on a table holding electrocardiograph with index fingers placed at the ECG electrode (left) and at the photoplethysmograph sensor(right).ECG signals are recorded from the fingers using first standard ECG lead. After registration, all ECG and photoplethysmography data will be sent to the server. The data will be automatically compared with a standard for data quality, after that the data will be sent to cardiologist. If quality will be not sufficient, the data will be deleted and the doctor will contact the patient to solve the quality issue. Thereafter, the parameters will be carried out by cardiologist, on the basis of which value of ECG monitoring will be estimated.
Study NCT03784742 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nitrate rich beetroot juice
Description: James White Drinks Limited beetroot juice (0.4-0.45 g nitrate/70 ml drink).
Study NCT03784742 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo beetroot juice
Description: James White Drinks Limited Placebo beetroot juice (0 nitrate/70 ml drink).
Study NCT00611923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutamide
Description: Participants will take one 125-mg flutamide capsule twice a day for two menstrual cycles. If a participant is unable to tolerate a twice-daily dose due to side effects, the dose will be reduced to one capsule per day.
Study NCT00611923 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take a lactose capsule twice a day for two menstrual cycles. If a participant is unable to tolerate a twice-daily dose due to side effects, the dose will be reduced to one capsule per day.
Study NCT00679211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine [Kadcyla]
Description: Intravenous repeating dose
Study NCT02199236 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: endorectal brachytherapy
Description: Patients will receive 3 fractions of endorectal brachytherapy, each spaced apart by 7 days (+/- 1 day). The three dose tiers will be 1500cGy (500cGy per fraction), 1800cGy (600cGy per fraction), and 2100cGy (700cGy per fraction).
Study NCT02199236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concurrent capecitabine or 5-FU
Description: Patients will receive 500 mg and 150 mg oral tablets of capecitabine for the prescribed dose of 825 mg/m2 BID, morning and evening (total daily dose of 1650 mg/m2 ). Dosages will be rounded to the nearest 150 mg or 500 mg. Tablets should be swallowed with water within 30 minutes after a meal. Capecitabine will be started on the Monday of the first week of brachytherapy (day 1) and taken on weekdays (Monday through Friday) during weeks of brachytherapy only.~Administration of 5-FU should be only by the intravenous route taking care to avoid extravasation. Patients will receive 225 mg/m2/day, as a continuous venous infusion by a portable pump for the 3 weeks of treatment. The infusional 5-FU will be exchanged every 7 days.
Study NCT02199236 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Patients should complete the 2 quality of life questionnaires during their follow-up appointments. If they are unable to be seen in follow-up, they may complete the questionnaires at home and email or mail them back to the investigator. Should there be any incomplete or ambiguous answers, a follow-up phone call will be made by a member of the research team for clarification. Additionally, if the questionnaires have not been returned within 3 weeks after the time when they are due, a member of the research team will call the patient, and the questions will be completed over the phone.
Study NCT01369251 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hygiene
Study NCT01369251 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual alcohol care
Study NCT01084005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linagliptin
Description: patients receive linagliptin 5 mg tablets once daily
Study NCT01084005 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patients receive placebo matching linagliptin 5 mg once daily
Study NCT03107351 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac contractility assessments with Kino-cardiograph
Description: Cardiac contractility will be assessed with Kino-cardiograph device. Echocardiography will also be used for the experimental arm
Study NCT03107351 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Cardiac assessment repeatability with Kino-cardiograph
Description: Cardiac contractility will be assessed with Kino-cardiograph device only, at different times of the day to assess the repeatability of the measures.
Study NCT01810796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Ranolazine versus placebo
Study NCT01823445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Xylitol disk
Study NCT02742181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvimopan
Description: Subjects diagnosed with a post operative ileus after surgery will be given alvimopan
Study NCT02742181 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Standard postoperative care
Study NCT03091530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleeper Stretch
Description: The sleeper stretch protocol will follow the process described by Wilk with the subject lying on his throwing shoulder side, with the lateral border of the scapula on the table, and the glenohumeral and elbow joints both at 90 degrees of flexion. Participants will be instructed to passively internally rotate the shoulder with gentle overpressure applied on the dorsum of the dominant arm wrist by the nondominant hand to the point of stretch on the posterior aspect of the shoulder. Stretches will be held for 20 seconds each and repeated 4 times for optimal sustained collagen elongation. This protocol will be performed on days 0-4 after the throwing session.
Study NCT03091530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 90/90 Hip Lift with Balloon Blow Exercise
Description: The 90/90 Hip Lift with Balloon Blow Exercise (BBE) will follow the guidelines described by the Postural Restoration Institute. The subjects will lie supine with hips and knees flexed to 90 degrees, the right arm flexed to end range and resting on the floor. Using the left arm to hold the balloon, subjects will inhale fully and exhale into a balloon while holding a posterior pelvic tilt. The subjects inhale and then exhale into the balloon fully, then hold their breath for 5 seconds while putting their tongue on the roof of their mouth.
Study NCT01078623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium 200 μg / formoterol 12 μg
Description: Aclidinium bromide 200 μg + formoterol fumarate 12 μg fixed dose combination (FDC) twice daily
Study NCT01078623 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control twice daily
Study NCT01078623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol 12 μg
Description: Formoterol fumarate 12 μg twice daily
Study NCT01078623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium 200 μg
Description: Aclidinium bromide 200 μg twice daily
Study NCT01078623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium 200 μg / Formoterol 6 μg
Description: Aclidinium bromide 200 μg + formoterol fumarate 6 μg fixed dose combination (FDC) twice daily
Study NCT00502541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluocinolone acetonide
Description: fluocinolone acetonide 0.59 mg intravitreal implant
Study NCT03690128 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: I-EWS with incorporated clinical assessment (Trigger Tool)
Description: In relation to systematic measurement of vital parameters the nursing staff will perform an individual clinical assessment of the patient and adjust the I-EWS score accordingly.
Study NCT03690128 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard EWS - Control (Trigger Tool)
Description: Standard EWS - Based on principles of National Early Warning Score (NEWS)
Study NCT01626196 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This was an observational study
Study NCT02617160 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MD-Logic Pump Advisor
Description: Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the MD-Logic Pump Advisor
Study NCT02617160 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team in accordance to the regular practice
Study NCT02391415 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VPM1002
Description: Tuberculosis vaccine
Study NCT02391415 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG
Description: commercially available live vaccine BCG
Study NCT02391415 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VPM1002(Hyg+)
Description: Tuberculosis vaccine
Study NCT00915018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Neratinib - 240 mg orally daily, administered once daily. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.
Study NCT00915018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab - 4 mg/kg IV initial loading dose followed by subsequent once weekly doses of 2mg/kg IV. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.
Study NCT00915018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel - 80 mg/m² IV administered on days 1, 8, and 15 of a 28-day cycle. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.
Study NCT00915018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel - 80 mg/m² IV administered on days 1, 8, and 15 of a 28-day cycle. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.
Study NCT01510301 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Mobile phone-based self-report system, electronic Patient-Reported Outcomes Measure (e-PROM)
Description: To test an electronic Patient-Reported Outcomes Measure (e-PROM) intended to assess patients' daily perceptions of symptoms and wellbeing, as well as self-measured blood pressure, treatment side-effects and medicine intake;~* Explore patient interactions (learning and understanding) with an internet-reporting system providing structured feedback of e-PROM results to examine if such feedback is useful in improving adherence;~* Explore patient-physician/nurse interactions to examine if structured feedback of e-PROM results serves as a useful complement to support consultations regarding treatment monitoring and adherence.
Study NCT00698672 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: charnley OGEE
Description: charnley OGEE
Study NCT00698672 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectron Reflection CoCr
Description: Spectron Reflection CoCr
Study NCT00698672 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectron XLPE CoCr
Description: Spectron XLPE CoCr
Study NCT00698672 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectron Reflection Oxinium
Description: Spectron Reflection Oxinium
Study NCT00698672 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectron XLPE CoCR
Description: Spectron XLPE CoCR
Study NCT01014169 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Note taking
Description: The mothers in the intervention group will be given a pen and encouraged to take written notes in the notes section of a discharge envelope using their language of preference when receiving standard newborn discharge information.
Study NCT03103152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose Aspirin & Vitamin D
Description: Aspirin 1 x 300mg tablet daily \& Vitamin D 4,000IU daily. (8 drops).
Study NCT03103152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose Aspirin, Vitamin D placebo
Description: Aspirin 1 x 300mg tablet daily \& Vitamin D placebo (8 drops).
Study NCT03103152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose Aspirin , Vitamin D
Description: Aspirin 1 x 100mg tablet daily \& Vitamin D 4,000IU daily. (8 drops).
Study NCT03103152 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low dose Aspirin, Vitamin D placebo
Description: Aspirin 1 x 100mg tablet daily \& Vitamin D placebo 8 drops daily.
Study NCT03103152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin Placebo, Vitamin D
Description: Aspirin 1 x 300mg placebo tablet daily \& Vitamin D 4,000IU daily. (8 drops).
Study NCT03103152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin placebo, Vitamin D placebo
Description: Aspirin 1 x 100mg placebo tablet daily \& Vitamin D 4,000IU daily. (8 drops).
Study NCT01780090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iPad software
Description: A specialized iPad application, entitled SpeechPrompts, has been developed to treat prosodic difficulties commonly seen in ASDs. SpeechPrompts provides the SLPs that work with students with ASDs an additional tool to treat prosody. The SpeechPrompts software offers visual support and biofeedback to change prosody. These two tools are not typically available for school-based SLPs.
Study NCT04560595 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caffeine Reduction Manual
Description: We will provide participants with a Guide to Caffeine Reduction and Cessation in order to help the reduce their caffeine use and determine their ratings of treatment acceptability.
Study NCT04515654 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IDEAS (Identity Evolution and Sharing) Performance
Description: 60 minute webinar depicting first-hand stories of transgender and gender non-conforming individuals followed by expert panel/talk-back
Study NCT04973150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: To explore whether pretreatment with eye covering can reduce the incidence of acute delirium and the score of delirium after general anesthesia in ophthalmology pre-age children.
Description: To explore whether pretreatment with eye covering can reduce the incidence of acute delirium and the score of delirium after general anesthesia in ophthalmology pre-age children. Methods A total of 300 preschool-age children who underwent general anesthesia of selective ophthalmic surgery in a 3A grade hospital from August 2019 to July 2020 were selected as the research object, who were divided into experimental group and control group with 150 cases each by random number table. Children in the control group received regular education on cartoon animation videos before surgery; children in the experimental group received eye-covering pretreatment on the basis of cartoon animation videos. The differences in preoperative anxiety degree score, postoperative acute delirium incidence, delirium degree score, and postoperative nursing care difficulty score were compared between the two groups.
Study NCT02445638 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole egg
Description: Subjects will be provided with the equivalent of 2 whole eggs daily.
Study NCT02445638 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Yolk-free egg
Description: Subjects will be provided with the equivalent of 2 yolk-free eggs daily.
Study NCT00751062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: timolol
Description: One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle.
Study NCT00751062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PhXA41
Description: One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle
Study NCT04722705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fractional Er:YAG laser
Description: At baseline, three lesions were randomized. Topical anesthetic cream was applied to the scar 30 minutes before laser treatment.~The same dermatologist performed 2,940 nm Er:YAG fractional laser. (long pulse mode, 1500mJ, 2Hz, 2 pass) The face was cooled after treatment with gauze soaked in ice water. The laser treatment was conducted total three sessions, immediately at suture removal, 4 weeks after suture removal and 8 weeks after suture removal. The evaluation of scar site was conducted 3 months later after last treatment.
Study NCT04722705 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fractional Er:YAG laser
Description: At baseline, three lesions were randomized. Topical anesthetic cream was applied to the scar 30 minutes before laser treatment.~The same dermatologist performed 2,940 nm Er:YAG fractional laser. (long pulse mode, 1500mJ, 2Hz, 2 pass) The face was cooled after treatment with gauze soaked in ice water. The laser treatment was conducted total three sessions, immediately at suture removal, 4 weeks after suture removal and 8 weeks after suture removal. The evaluation of scar site was conducted 3 months later after last treatment.
Study NCT04722705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intense pulse light
Description: At baseline, three lesions were randomized. Topical anesthetic cream was applied to the scar 30 minutes before laser treatment.~The same dermatologist performed IPL. (irridation energy: 12.5J/cm2, pulse duration: 10ms, 1pass) The face was cooled after treatment with gauze soaked in ice water. The laser treatment was conducted total three sessions, immediately at suture removal, 4 weeks after suture removal and 8 weeks after suture removal. The evaluation of scar site was conducted 3 months later after last treatment.
Study NCT03039764 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapael
Description: This group will receive virtual reality-based rehabilitation intervention wearing Rapael glove made by Neofect supplemented with standard occupational services per conventional protocols.
Study NCT01661335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron, dexamethasone, aprepitant
Description: Ondansetron 0.15 mg/kg (max 16 mg) IV or PO every 8 hours for at least 3 days, but no longer than 5 days; dexamethasone 0.2mg/kg (max 10 mg) IV or PO daily for at least 3 days, but no longer than 5 days; and aprepitant 3 mg/kg (max 125 mg) PO on day 1, and aprepitant 2 mg/kg (max 80 mg) PO on days 2 and 3 during the first investigational antiemetic cycle. During the next investigational antiemetic cycle, members of this arm will be crossed-over into the placebo arm, where the aprepitant will be replaced by placebo and the dexamethasone dose will be increased to 0.4 mg/kg (max 20 mg) daily.
Study NCT01661335 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron, Dexamethasone, placebo
Description: Ondansetron 0.15 mg/kg (max 16 mg) IV or PO every 8 hours for at least 3 days, but no more than 5 days; dexamethasone 0.4 mg/kg (max 20 mg) IV or PO daily for at least 3 days, but no more than 5 days; and a PO placebo for 3 days during the first investigational antiemetic cycle. During the second cycle, members this group will be crossed-over to the experimental arm, where the placebo will be replaced by aprepitant and the dexamethasone will be decreased by 50%.
Study NCT04934813 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alveolar ridge preservation
Description: application of different bone graft and sealing means after tooth extraction
Study NCT03885895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid Injectable Product
Description: Ampoules used for intradermal injection